

Date: 19th December, 2022

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla
Complex, Bandra (E), Mumbai – 400 051

Dear Sir / Madam,

Subject: USFDA inspection at Alembic Pharmaceuticals' Solid Oral Formulation Facility (F-4) at Jarod

We would like to inform that the United States Food and Drug Administration (USFDA) has conducted PAI (Pre-Approval Inspection) at Alembic Pharmaceuticals' Solid Oral Formulation Facility (F-4) located at Jarod. The USFDA issued a Form 483 with 5 procedural observations.

None of the observations are related to data integrity and management believes that they are addressable.

The Company is preparing the response to the observations, which will be submitted to the USFDA within stipulated period.

The Company is committed to maintain the highest quality standards and compliance at all times.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED